- Home
- BEAT vs RDI Comparison
BEAT vs RDI Comparison
Compare BEAT & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAT
- RDI
- Stock Information
- Founded
- BEAT 2015
- RDI 1937
- Country
- BEAT United States
- RDI United States
- Employees
- BEAT N/A
- RDI N/A
- Industry
- BEAT Retail: Computer Software & Peripheral Equipment
- RDI Movies/Entertainment
- Sector
- BEAT Technology
- RDI Consumer Discretionary
- Exchange
- BEAT Nasdaq
- RDI Nasdaq
- Market Cap
- BEAT 33.1M
- RDI 27.9M
- IPO Year
- BEAT 2021
- RDI N/A
- Fundamental
- Price
- BEAT $1.03
- RDI $1.40
- Analyst Decision
- BEAT Buy
- RDI
- Analyst Count
- BEAT 1
- RDI 0
- Target Price
- BEAT $8.00
- RDI N/A
- AVG Volume (30 Days)
- BEAT 118.9K
- RDI 52.3K
- Earning Date
- BEAT 08-13-2025
- RDI 08-14-2025
- Dividend Yield
- BEAT N/A
- RDI N/A
- EPS Growth
- BEAT N/A
- RDI N/A
- EPS
- BEAT N/A
- RDI N/A
- Revenue
- BEAT N/A
- RDI $219,213,000.00
- Revenue This Year
- BEAT N/A
- RDI $7.47
- Revenue Next Year
- BEAT N/A
- RDI $13.22
- P/E Ratio
- BEAT N/A
- RDI N/A
- Revenue Growth
- BEAT N/A
- RDI 7.59
- 52 Week Low
- BEAT $0.91
- RDI $1.17
- 52 Week High
- BEAT $3.48
- RDI $1.89
- Technical
- Relative Strength Index (RSI)
- BEAT 40.15
- RDI 56.96
- Support Level
- BEAT $0.91
- RDI $1.33
- Resistance Level
- BEAT $1.32
- RDI $1.47
- Average True Range (ATR)
- BEAT 0.12
- RDI 0.06
- MACD
- BEAT 0.01
- RDI 0.01
- Stochastic Oscillator
- BEAT 29.27
- RDI 70.83
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.